Terns is interested in partnering with life science and biopharmaceutical companies to rapidly advance its growing pipeline of compounds targeting liver diseases, cancer and infectious diseases, and bring those drugs to patients globally.

If you are interested in investing in Terns, or learning more about our business development efforts, please contact us.

Recent Funding

Terns completed a $80 million Series B financing in Oct 2018. Financing led by Vivo Capital and OrbiMed, joined by Decheng Capital and Lilly Asia Ventures.

Terns closed a $30 million Series A funding from Lilly Asia Ventures in April 2017.